Hipra’s Eravac for rabbit haemorrhagic disease approved by EMA

Eravac, the first single dose vaccine for the prevention of type-2 haemorrhagic disease in pet rabbits, has now been approved for use in the EU by the EMA for the active immunisation of rabbits from 30 days old. It contains inactivated RHD type 2 virus, strain (V-1037), and an adjuvant to enhance the immune response. The injection is only on prescription, and protection starts one week after vaccination and lasts nine months.
Rabbit haemorrhagic disease is caused by a new variant RHD type 2 virus which causes blood clots and is often fatal. Eravac was compared with placebo in three laboratory studies involving 301 rabbits. In the first study 100% Eravac vaccinated rabbits survived versus 37% survival rate with placebo. In the second study 93% Eravac vaccinated rabbits survived versus 50% of rabbits given placebo. In the third study 100% Eravac vaccinated rabbits survived versus 69% given placebo.